Cargando…

Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial

BACKGROUND: The randomized clinical trial, SafeBoosC II, examined the effect of monitoring of cerebral oxygenation by near-infrared spectroscopy combined with a guideline on treatment when cerebral oxygenation was out of the target range. Data on cerebral oxygenation was collected in both the interv...

Descripción completa

Detalles Bibliográficos
Autores principales: Plomgaard, Anne M., Alderliesten, Thomas, Austin, Topun, van Bel, Frank, Benders, Manon, Claris, Olivier, Dempsey, Eugene, Fumagalli, Monica, Gluud, Christian, Hagmann, Cornelia, Hyttel-Sorensen, Simon, Lemmers, Petra, van Oeveren, Wim, Pellicer, Adelina, Petersen, Tue H., Pichler, Gerhard, Winkel, Per, Greisen, Gorm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362210/
https://www.ncbi.nlm.nih.gov/pubmed/28328980
http://dx.doi.org/10.1371/journal.pone.0173440
_version_ 1782516921542901760
author Plomgaard, Anne M.
Alderliesten, Thomas
Austin, Topun
van Bel, Frank
Benders, Manon
Claris, Olivier
Dempsey, Eugene
Fumagalli, Monica
Gluud, Christian
Hagmann, Cornelia
Hyttel-Sorensen, Simon
Lemmers, Petra
van Oeveren, Wim
Pellicer, Adelina
Petersen, Tue H.
Pichler, Gerhard
Winkel, Per
Greisen, Gorm
author_facet Plomgaard, Anne M.
Alderliesten, Thomas
Austin, Topun
van Bel, Frank
Benders, Manon
Claris, Olivier
Dempsey, Eugene
Fumagalli, Monica
Gluud, Christian
Hagmann, Cornelia
Hyttel-Sorensen, Simon
Lemmers, Petra
van Oeveren, Wim
Pellicer, Adelina
Petersen, Tue H.
Pichler, Gerhard
Winkel, Per
Greisen, Gorm
author_sort Plomgaard, Anne M.
collection PubMed
description BACKGROUND: The randomized clinical trial, SafeBoosC II, examined the effect of monitoring of cerebral oxygenation by near-infrared spectroscopy combined with a guideline on treatment when cerebral oxygenation was out of the target range. Data on cerebral oxygenation was collected in both the intervention and the control group. The primary outcome was the reduction in the burden of cerebral hypo- and hyperoxia between the two groups. In this study we describe the associations between the burden of cerebral hypo- and hyperoxia, regardless of allocation to intervention or control group, and the biomarkers of brain injury from birth till term equivalent age that was collected as secondary and explorative outcomes in the SafeBoosC II trial. METHODS: Cerebral oxygenation was continuously monitored during the first 72h of life in 166 extremely preterm infants. Cranial ultrasound was performed at day 1,4,7,14, and 35 and at term. Electroencephalogram (EEG) was recorded at 64h. Blood-samples taken at 6 and 64 hours were analysed for the brain injury biomarkers; S100beta, brain-fatty-acid-binding-protein, and neuroketal. All analyses were conducted post hoc. RESULTS: Significantly more infants with a cerebral burden of hypoxia within the 4(th) quartile versus infants within quartile 1–3 were diagnosed with severe intracranial haemorrhage (11/39 versus 11/117, p = 0.003), had low burst rate on EEG (12/28 versus 21/103, p = 0.015), or died (14/41 versus 18/123, p = 0.006), whereas none of these events were significantly associated with cerebral hyperoxia. The blood biomarkers were not significantly associated with the burden of cerebral hypo- or hyperoxia. CONCLUSIONS: The explorative analysis showed that early burden of cerebral hypoxia, but not hyperoxia was significantly associated with low brain electrical activity and severe intracranial haemorrhage while none of the three blood biomarkers were associated with the burden of either cerebral hypo- or hyperoxia.
format Online
Article
Text
id pubmed-5362210
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53622102017-04-06 Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial Plomgaard, Anne M. Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Fumagalli, Monica Gluud, Christian Hagmann, Cornelia Hyttel-Sorensen, Simon Lemmers, Petra van Oeveren, Wim Pellicer, Adelina Petersen, Tue H. Pichler, Gerhard Winkel, Per Greisen, Gorm PLoS One Research Article BACKGROUND: The randomized clinical trial, SafeBoosC II, examined the effect of monitoring of cerebral oxygenation by near-infrared spectroscopy combined with a guideline on treatment when cerebral oxygenation was out of the target range. Data on cerebral oxygenation was collected in both the intervention and the control group. The primary outcome was the reduction in the burden of cerebral hypo- and hyperoxia between the two groups. In this study we describe the associations between the burden of cerebral hypo- and hyperoxia, regardless of allocation to intervention or control group, and the biomarkers of brain injury from birth till term equivalent age that was collected as secondary and explorative outcomes in the SafeBoosC II trial. METHODS: Cerebral oxygenation was continuously monitored during the first 72h of life in 166 extremely preterm infants. Cranial ultrasound was performed at day 1,4,7,14, and 35 and at term. Electroencephalogram (EEG) was recorded at 64h. Blood-samples taken at 6 and 64 hours were analysed for the brain injury biomarkers; S100beta, brain-fatty-acid-binding-protein, and neuroketal. All analyses were conducted post hoc. RESULTS: Significantly more infants with a cerebral burden of hypoxia within the 4(th) quartile versus infants within quartile 1–3 were diagnosed with severe intracranial haemorrhage (11/39 versus 11/117, p = 0.003), had low burst rate on EEG (12/28 versus 21/103, p = 0.015), or died (14/41 versus 18/123, p = 0.006), whereas none of these events were significantly associated with cerebral hyperoxia. The blood biomarkers were not significantly associated with the burden of cerebral hypo- or hyperoxia. CONCLUSIONS: The explorative analysis showed that early burden of cerebral hypoxia, but not hyperoxia was significantly associated with low brain electrical activity and severe intracranial haemorrhage while none of the three blood biomarkers were associated with the burden of either cerebral hypo- or hyperoxia. Public Library of Science 2017-03-22 /pmc/articles/PMC5362210/ /pubmed/28328980 http://dx.doi.org/10.1371/journal.pone.0173440 Text en © 2017 Plomgaard et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Plomgaard, Anne M.
Alderliesten, Thomas
Austin, Topun
van Bel, Frank
Benders, Manon
Claris, Olivier
Dempsey, Eugene
Fumagalli, Monica
Gluud, Christian
Hagmann, Cornelia
Hyttel-Sorensen, Simon
Lemmers, Petra
van Oeveren, Wim
Pellicer, Adelina
Petersen, Tue H.
Pichler, Gerhard
Winkel, Per
Greisen, Gorm
Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
title Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
title_full Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
title_fullStr Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
title_full_unstemmed Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
title_short Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
title_sort early biomarkers of brain injury and cerebral hypo- and hyperoxia in the safeboosc ii trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362210/
https://www.ncbi.nlm.nih.gov/pubmed/28328980
http://dx.doi.org/10.1371/journal.pone.0173440
work_keys_str_mv AT plomgaardannem earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT alderliestenthomas earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT austintopun earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT vanbelfrank earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT bendersmanon earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT clarisolivier earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT dempseyeugene earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT fumagallimonica earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT gluudchristian earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT hagmanncornelia earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT hyttelsorensensimon earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT lemmerspetra earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT vanoeverenwim earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT pelliceradelina earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT petersentueh earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT pichlergerhard earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT winkelper earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial
AT greisengorm earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial